Clinical Trial Update: Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia [EARLY_Phase 1]

View source ↗

Summary

This early-phase trial update describes a study evaluating momelotinib in combination with a hypomethylating agent for Chronic Myelomonocytic Leukemia, Myelodys…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes
• Myelomonocytic Leukemia
• Myeloproliferative Overlap Neoplasms
• Neutrophilic Leukemia

Drugs mentioned

• Hypomethylating agent (unspecified)
• Momelotinib (momelotinib)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes | EARLY_Phase 1 | Status: RECRUITING